US Merger & Acquisition SEC Filings — July 27, 2026

27-07-2026

International Media Acquisition Corp. (IMAQW) extended its deadline to complete an initial business combination by one month, from August 2, 2026 to September 2, 2026, by depositing $2,000 into its trust account. This is the 20th of 24 permitted monthly extensions, indicating the company has been unable to consummate a merger for nearly 20 months and is running low on available extensions. The filing does not disclose any new target or progress toward a deal.

• · The extension moves the deadline from August 2, 2026 to September 2, 2026.
• · This is the 20th extension letter out of a total of 24 permitted under the Trust Agreement.
• · The trust agreement was originally dated July 28, 2021 and has been amended multiple times (July 26, 2022; January 27, 2023; July 31, 2023; January 2, 2024; December 31, 2024).
• · The company's securities (IMAQ, IMAQW, IMAQR, IMAQU) are not listed on any exchange (trading symbol column shows 'None').

27-07-2026

Translational Development Acquisition Corp. (TDAC) entered into a Subscription Agreement on July 27, 2026, with ProLogium Holding Inc. and a subscriber for the sale of securities in connection with a business combination. The subscriber, an accredited investor, will purchase ordinary shares and warrants exercisable at $11.50 per share, with proceeds expected to fund the combination. The filing notes forward-looking risks including potential delays, shareholder approval failures, and redemption requests, and the registration statement for the business combination has not yet been declared effective.

• · The Subscription Agreement was filed as Exhibit 10.1, with certain schedules omitted and confidential information redacted.
• · The subscriber is an accredited investor and institutional account, and the securities are being sold under Section 4(a)(2) of the Securities Act.
• · The registration statement on Form F-4 for the business combination has not yet been declared effective by the SEC.
• · TDAC is a blank check company, so the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995 is not available.

27-07-2026

Lattice Semiconductor completed its acquisition of AMI on July 27, 2026, creating what it describes as the industry's most complete secure management and control platform for data center AI and physical AI. The deal is expected to be accretive to gross margin, free cash flow, and non-GAAP EPS, and supports Lattice's trajectory toward a $1 billion or greater annual revenue run rate by end of 2026. AMI will operate as a dedicated, silicon-neutral business unit under its existing leadership, preserving its open approach to platform firmware.

• · Acquisition was first announced on May 4, 2026.
• · Lattice expects to provide additional information on AMI’s operating results and anticipated future performance when it reports its second quarter 2026 results on August 4, 2026.
• · The AMI business unit will continue to be led by long-time AMI CEO Sanjoy Maity, reporting directly to CEO Ford Tamer.
• · AMI's firmware and manageability solutions will continue to be developed and delivered without preference for any silicon vendor, including Lattice.

27-07-2026

Future Vision II Acquisition Corp. held an extraordinary general meeting on July 23, 2026, where shareholders approved all six proposals, including the business combination with MicroTouch Inc., a name change to MicroTouch Inc., Nasdaq listing issuance, charter amendments, director elections, and adjournment. All proposals passed with overwhelming support (over 97% of votes cast in favor for most items), except the charter amendment which received 94.4% approval. However, 3,758,515 public ordinary shares (approximately 65% of the public float) were tendered for redemption at an estimated $10.97 per share, which will reduce the trust account to about $21.8 million post-closing, and the business combination remains subject to Nasdaq listing approval and other closing conditions.

• · The redemption of 3,758,515 shares is contingent upon the legal consummation of the Business Combination; if the deal fails, the shares will not be redeemed and will remain outstanding.
• · If the closing is significantly delayed, the Company may need to hold an Extension Meeting, at which shareholders would have a new, independent redemption opportunity that would be paid out promptly regardless of the Business Combination's ultimate consummation.
• · The final per-share redemption price will be calculated two business days before actual closing, potentially higher than the $10.97 estimate due to continued interest accrual and possible sponsor extension loans.
• · The Company must obtain initial listing approval from Nasdaq as a closing condition; there is no assurance this will be satisfied.

27-07-2026

Snow Rothschild Acquisition Corp. announced that holders of its IPO units may elect to separately trade the Class A ordinary shares and warrants commencing July 30, 2026. The units, shares, and warrants will trade on Nasdaq under symbols ISNRU, ISNR, and ISNRW respectively. No fractional warrants will be issued.

• · Separate trading commences on July 30, 2026.
• · Holders must have their brokers contact Continental Stock Transfer & Trust Company to separate units.
• · The company is a blank check company focused on industrial assets and other industries.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.

27-07-2026

Novanta Inc. completed its acquisition of Riverpoint Medical from Arlington Capital Partners on July 27, 2026. Riverpoint is a category leader in high-growth minimally invasive surgical consumables, and the deal is expected to double Novanta's recurring medical consumables revenue to roughly $300 million, push medical end-market exposure to 60% of total revenue, and unlock a $2 billion incremental addressable market. The transaction is expected to be immediately accretive to organic growth, adjusted gross margins, adjusted EBITDA, and cash flows, with an estimated $0.18 to $0.25 adjusted EPS contribution in 2027.

• · Riverpoint Medical will be reported under Novanta's Medical Solutions operating segment.
• · The transaction is expected to generate a high single-digit return on invested capital by year three and achieve the Company's return hurdle rate by year five.
• · Additional detail on the impact to Novanta's 2026 financials will be provided on the upcoming second quarter earnings call.
• · Riverpoint Medical is headquartered in Portland, Oregon, with manufacturing operations in Portland, Oregon and San Jose, Costa Rica.
• · Arlington Capital Partners is currently investing out of its $6 billion Fund VII.

27-07-2026

AiRWA Inc. (YYAI) announced a definitive agreement to acquire Hongkong Best Life Trade Co., Limited for a base purchase price of $50 million, with additional contingent earn-out payments of up to $80 million based on revenue milestones. The acquisition aims to diversify AiRWA's revenue base beyond its core AI data training business and reduce reliance on technology licensing and social media advertising, where profitability has been under pressure. However, the company also noted delays in its previously announced RWA-focused exchange joint venture, and the acquisition is subject to customary closing conditions.

• · Best Life has operated for more than a decade specializing in import/export between Japan, Hong Kong, and mainland China.
• · Best Life operates through a subsidiary in the UK and is establishing subsidiaries in the US, Canada, and New Zealand.
• · Best Life's customer base includes Alibaba Health Hong Kong, AlipayHK, Tmall, Taobao, and Cainiao, each with formal cooperation agreements.
• · AiRWA's AI-focused subsidiary, 26 Rafael, continues to perform in line with management's expectations.
• · Social media advertising revenue has remained resilient but profitability has been under pressure.
• · The company has experienced delays in its previously announced plans for an RWA-focused exchange joint venture.
• · The acquisition is subject to customary closing conditions.